← Leaderboards

Christopher Miller

University Of California Davis

Google Scholar ↗PubMed ↗ORCID ↗

$37,492,368

Attributed

$38,826,966

Total exposure

52

Grants

32

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.8M · FY2005–19

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

Funding mix

By agency

NIH$53,442,124 · 54

By mechanism

R01$20,087,484 · 7

P01$17,455,446 · 6

P51$6,701,469 · 35

U19$6,085,918 · 2

R24$2,667,855 · 1

R21$312,234 · 1

Top collaborators

Donald N Forthal4 shared

Most similar at University Of California Davis

Same institution · by research overlap

Marta L Marthas$7,401,608
Paul A Luciw$9,374,467
Tilahun D Yilma$5,862,063

Others in their field

Top investigators on “Macaca Mulatta”

Barton F Haynes · Duke University$291,595,855
Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
Richard A Gibbs · Baylor College Of Medicine$82,928,769
Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
David I Watkins · George Washington University$57,087,952
Rama Rao Amara · Emory University$54,145,017

Research focus

Macaca MulattaVaccinesImmune ResponseInfectionVirusPreventTransmission ProcessFundingHiv InfectionsUnited States National Institutes Of HealthAnimalsGenital SystemGrantResourcesSourceTissuesPrimatesInstitutionHiv-1FemaleSimian Immunodeficiency VirusVaginaComputer Retrieval Of Information On Scientific Projects DatabaseResearch Personnel

Grant awards (93)

How did a vaccine enhance HIV acquisition$600,134

R01 · FY2019 · AI · contact PI

How did a vaccine enhance HIV acquisition$614,239

R01 · FY2018 · AI · contact PI

How did a vaccine enhance HIV acquisition$697,049

R01 · FY2017 · AI · contact PI

Modeling Inflammation in HIV Transmission$1,019,992

R01 · FY2016 · AI · contact PI

How did a vaccine enhance HIV acquisition$692,018

R01 · FY2016 · AI · contact PI

A NHP model for vaginal Zika Virus transmission$312,234

R21 · FY2016 · OD · contact PI

Modeling Inflammation in HIV Transmission$1,013,349

R01 · FY2015 · AI · contact PI

How did a vaccine enhance HIV acquisition$713,482

R01 · FY2015 · AI · contact PI

SIV Transmission in Male NHP$693,573

R01 · FY2015 · AI · contact PI

The impact of antibody and pH on female-to-male SIV infection$663,075

R01 · FY2015 · AI

Modeling Inflammation in HIV Transmission$1,108,673

R01 · FY2014 · AI · contact PI

SIV Transmission in Male NHP$707,408

R01 · FY2014 · AI · contact PI

The impact of antibody and pH on female-to-male SIV infection$682,866

R01 · FY2014 · AI

Modeling Inflammation in HIV Transmission$984,098

R01 · FY2013 · AI · contact PI

SIV Transmission in Male NHP$682,672

R01 · FY2013 · AI · contact PI

The impact of antibody and pH on female-to-male SIV infection$641,194

R01 · FY2013 · AI

SIV Transmission in Male NHP$722,403

R01 · FY2012 · AI · contact PI

The impact of antibody and pH on female-to-male SIV infection$682,061

R01 · FY2012 · AI

SIV Transmission in Male NHP$723,453

R01 · FY2011 · AI · contact PI

MECHANISMS OF PROTECTION FROM AND ENHANCED SUSCEPTIBILITY TO HIV INFECTION$191,444

P51 · FY2011 · RR · contact PI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$191,444

P51 · FY2011 · RR · contact PI

EVALUATION OF THE EFFICACY OF AN HIV VACCINE$47,945

P51 · FY2011 · RR · contact PI

Mechanisms of protection from, and enhanced susceptibility to, HIV infection afte$1,795,378

P01 · FY2010 · AI · contact PI

MECHANISMS OF PROTECTION FROM AND ENHANCED SUSCEPTIBILITY TO HIV INFECTION$152,095

P51 · FY2010 · RR · contact PI

INNATE IMMUNE RECEPTORS & ADJUVANT DISCOVERY$152,094

P51 · FY2010 · RR · contact PI

NHP MODEL TO EVALUATE CS IMPACT OF HIV ACQUISIONS$152,094

P51 · FY2010 · RR · contact PI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$152,094

P51 · FY2010 · RR · contact PI

Mechanisms of protection from, and enhanced susceptibility to, HIV infection afte$2,294,327

P01 · FY2009 · AI · contact PI

Supplement to Mechanisms of Protection in Live-attenuated AIDS Vaccines$281,115

P01 · FY2009 · AI · contact PI

Mechanisms of Protection in Live-attenuated AIDS Vaccin*$281,115

P01 · FY2009 · AI · contact PI

NHP MODEL TO EVALUATE CS IMPACT OF HIV ACQUISIONS$146,581

P51 · FY2009 · RR · contact PI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$146,579

P51 · FY2009 · RR · contact PI

INNATE IMMUNE RECEPTORS & ADJUVANT DISCOVERY$143,537

P51 · FY2009 · RR · contact PI

Mechanisms of Protection in Live-attenuated AIDS Vaccin*$2,186,950

P01 · FY2008 · AI · contact PI

Core--Primate$716,138

P01 · FY2008 · AI · contact PI

Adaptive Immunity in Live-Attenuated AIDS Vaccines$498,463

P01 · FY2008 · AI · contact PI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$168,995

P51 · FY2008 · RR · contact PI

Mechanisms of Protection in Live-attenuated AIDS Vaccin*$2,297,366

P01 · FY2007 · AI · contact PI

Core--Primate$809,273

P01 · FY2007 · AI · contact PI

Adaptive Immunity in Live-Attenuated AIDS Vaccines$504,097

P01 · FY2007 · AI · contact PI

HIV-1 VACCINES DESIGNED TO INDUCE MUCOSAL IMMUNITY$181,569

P51 · FY2007 · RR · contact PI

MUCOSAL AND SYSTEMIC ANTI-HIV VACCINES MACAQUES$181,569

P51 · FY2007 · RR · contact PI

EFFECT OF MICROBICIDES ON MUCOSAL HIV TRANSMISSION$181,569

P51 · FY2007 · RR · contact PI

SIV TARGET CELLS IN VAGINAL TRANSMISSION$181,569

P51 · FY2007 · RR · contact PI

ANTI-IFNA ANTIBODY ON VIRUS REPLICATION IN CHRONIC CMV & SIV CO-INFECTED RHESUS$181,569

P51 · FY2007 · RR · contact PI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$181,569

P51 · FY2007 · RR · contact PI

25th Annual Symposium on Nonhuman Primate Models for AIDS$73,089

R13 · FY2007 · RR · contact PI

Mechanisms of Protection in Live-attenuated AIDS Vaccin*$1,969,451

P01 · FY2006 · AI · contact PI

Core--Primate$536,979

P01 · FY2006 · AI · contact PI

Adaptive Immunity in Live-Attenuated AIDS Vaccines$450,268

P01 · FY2006 · AI · contact PI

HIV-1 VACCINES DESIGNED TO INDUCE MUCOSAL IMMUNITY$156,653

P51 · FY2006 · RR · contact PI

MUCOSAL AND SYSTEMIC ANTI-HIV VACCINES MACAQUES$156,653

P51 · FY2006 · RR · contact PI

EFFECT OF MICROBICIDES ON MUCOSAL HIV TRANSMISSION$156,653

P51 · FY2006 · RR · contact PI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$156,653

P51 · FY2006 · RR · contact PI

ANTI-IFNA ANTIBODY ON VIRUS REPLICATION IN CHRONIC CMV & SIV CO-INFECTED RHESUS$156,653

P51 · FY2006 · RR · contact PI

SIV TARGET CELLS IN VAGINAL TRANSMISSION$156,653

P51 · FY2006 · RR · contact PI

Mechanisms of Protection in Live-attenuated AIDS Vaccin*$1,794,358

P01 · FY2005 · AI

Core--Primate$504,507

P01 · FY2005 · AI

Adaptive Immunity in Live-Attenuated AIDS Vaccines$398,924

P01 · FY2005 · AI

SIV TARGET CELLS IN VAGINAL TRANSMISSION$207,459

P51 · FY2005 · RR

HIV-1 VACCINES DESIGNED TO INDUCE MUCOSAL IMMUNITY$207,141

P51 · FY2005 · RR

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$207,141

P51 · FY2005 · RR

EFFECT OF MICROBICIDES ON MUCOSAL HIV TRANSMISSION$207,141

P51 · FY2005 · RR

ANTI-IFNA ANTIBODY ON VIRUS REPLICATION IN CHRONIC CMV &SIV CO-INFECTED RHESUS$207,141

P51 · FY2005 · RR

Administrative Core$136,737

P01 · FY2005 · AI

PROTECTION AGAINST RESPIRATORY PATHOGENS WITH OLIGONUCLEOTIDE CPG$110,902

P51 · FY2005 · RR

HIV-1 Vaccines Designed to Induce Mucosal Immunity$2,028,178

U19 · FY2004 · AI

Effect of Microbicides on Mucosal HIV Transmission$1,228,872

R01 · FY2004 · AI

HIV-1 VACCINES DESIGNED TO INDUCE MUCOSAL IMMUNITY$714,678

P51 · FY2004 · RR

EFFECT OF MICROBICIDES ON MUCOSAL HIV TRANSMISSION$350,632

P51 · FY2004 · RR

HIV VACCINES BASED WITH BOOST WITH WHOLE KILLED VIRUS$122,318

P51 · FY2004 · RR

IMMUNOLOGY CORE SERVICES$97,367

P51 · FY2004 · RR

ANTI-IFNA ANTIBODY ON VIRUS REPLICATION IN CHRONIC CMV$28,047

P51 · FY2004 · RR

PROTECTION AGAINST A CONTAGIOUS RESPIRATORY PATHOGEN$16,978

P51 · FY2004 · RR

SIV TARGET CELLS IN VAGINAL TRANSMISSION$470

P51 · FY2004 · RR

HIV-1 Vaccines Designed to Induce Mucosal Immunity$2,433,228

U19 · FY2003 · AI

Effect of Microbicides on Mucosal HIV Transmission$1,193,789

R01 · FY2003 · AI

DEVELOPMENT OF THE PRIMATE IMMUNOLOGY RESOURCE$703,649

R24 · FY2003 · RR

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINES$234,252

P51 · FY2003 · RR

SIV TARGET CELLS IN VAGINAL TRANSMISSION$184,678

P51 · FY2003 · RR

ANNUAL SYMPOSIUM ON NONHUMAN PRIMATE MODELS FOR AIDS$72,479

P51 · FY2003 · RR

DEVELOPMENT OF THE PRIMATE IMMUNOLOGY RESOURCE$58,411

P51 · FY2003 · RR

HIV-1 Vaccines Designed to Induce Mucosal Immunity$1,624,512

U19 · FY2002 · AI

Effect of Microbicides on Mucosal HIV Transmission$1,336,892

R01 · FY2002 · AI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINE$797,663

R01 · FY2002 · AI

DEVELOPMENT OF THE PRIMATE IMMUNOLOGY RESOURCE$684,429

R24 · FY2002 · RR

ANNUAL SYMPOSIUM ON NONHUMAN PRIMATE MODELS FOR AIDS$58,629

R13 · FY2002 · RR

HIV Vaccines to Elicit Mucosal Immunity in Primates$0

U19 · FY2002 · AI

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINE$859,182

R01 · FY2001 · AI

DEVELOPMENT OF THE PRIMATE IMMUNOLOGY RESOURCE$663,901

R24 · FY2001 · RR

PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINE$811,239

R01 · FY2000 · AI

DEVELOPMENT OF THE PRIMATE IMMUNOLOGY RESOURCE$615,876

R24 · FY2000 · RR

MUCOSAL IMMUNIZATION AGAINST GENITAL TRASMISSION OF SIV$218,108

R01 · FY2000 · AI